203 related articles for article (PubMed ID: 1346236)
21. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival.
Raspollini MR; Amunni G; Villanucci A; Castiglione F; Rossi Degl'Innocenti D; Baroni G; Paglierani M; Taddei GL
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):181-6. PubMed ID: 16785787
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
23. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
24. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.
Oh JJ; Grosshans DR; Wong SG; Slamon DJ
Nucleic Acids Res; 1999 Oct; 27(20):4008-17. PubMed ID: 10497265
[TBL] [Abstract][Full Text] [Related]
25. Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression.
Shiga K; Shiga C; Sasano H; Miyazaki S; Yamamoto T; Yamamoto M; Hayashi N; Nishihira T; Mori S
Anticancer Res; 1993; 13(5A):1293-301. PubMed ID: 7902061
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
27. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
Hsieh CY; Chen CA; Chou CH; Lai KP; Jeng YM; Kuo ML; Wei LH
J Biomed Sci; 2004; 11(2):249-59. PubMed ID: 14966375
[TBL] [Abstract][Full Text] [Related]
29. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma.
Naber SP; Tsutsumi Y; Yin S; Zolnay SA; Mobtaker H; Marks PJ; McKenzie SJ; DeLellis RA; Wolfe HJ
Am J Clin Pathol; 1990 Aug; 94(2):125-36. PubMed ID: 1973590
[TBL] [Abstract][Full Text] [Related]
30. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues.
Lee H; Maihle NJ
Oncogene; 1998 Jun; 16(25):3243-52. PubMed ID: 9681822
[TBL] [Abstract][Full Text] [Related]
31. Immunologic characterization of tumor markers in human ovarian cancer cell lines.
Kutteh WH; Miller DS; Mathis JM
J Soc Gynecol Investig; 1996; 3(4):216-22. PubMed ID: 8796833
[TBL] [Abstract][Full Text] [Related]
32. Neu oncogene expression in ovarian tumors: a quantitative study.
Huettner PC; Carney WP; Naber SP; DeLellis RA; Membrino W; Wolfe HJ
Mod Pathol; 1992 May; 5(3):250-6. PubMed ID: 1353878
[TBL] [Abstract][Full Text] [Related]
33. Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.
Hung MC; Yan DH; Zhao XY
Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2545-8. PubMed ID: 2565034
[TBL] [Abstract][Full Text] [Related]
34. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
Karlan BY; Jones J; Slamon DJ; Lagasse LD
Gynecol Oncol; 1994 Apr; 53(1):70-7. PubMed ID: 7909787
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
36. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness.
Sugano S; Mukai K; Tsuda H; Hirohashi S; Furuya S; Shimosato Y; Ebihara S; Takeyama I
Laryngoscope; 1992 Aug; 102(8):923-7. PubMed ID: 1353853
[TBL] [Abstract][Full Text] [Related]
38. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
39. [Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells].
Marth C; Müller-Holzner E; Zeimet AG; Greiter E; Cronauer MV; Doppler W; Eibl B; Hynes NE; Daxenbichler G
Gynakol Geburtshilfliche Rundsch; 1992; 32(1):31-4. PubMed ID: 1355379
[TBL] [Abstract][Full Text] [Related]
40. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Slamon DJ; Godolphin W; Jones LA; Holt JA; Wong SG; Keith DE; Levin WJ; Stuart SG; Udove J; Ullrich A
Science; 1989 May; 244(4905):707-12. PubMed ID: 2470152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
